Discounted Cash Flow (DCF) Analysis Levered

Summit Therapeutics Inc. (SMMT)

$1.21

0.00 (0.00%)
All numbers are in Millions, Currency in USD
Stock DCF: -974.08 | 1.21 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 2.8835.9856.410.8600.010.020.080.280.98
Revenue (%)
Operating Cash Flow 15.18-20.79-35.14-48.11-72.59-51.16-180.08-633.81-2,230.80-7,851.69
Operating Cash Flow (%)
Capital Expenditure -0.11-0.68-0.16-0.42-0-0-0-0.01-0.04-0.13
Capital Expenditure (%)
Free Cash Flow 15.07-21.47-35.31-48.53-72.59-51.16-180.08-633.82-2,230.84-7,851.83

Weighted Average Cost Of Capital

Share price $ 1.21
Beta 0.955
Diluted Shares Outstanding 92.29
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.473
Total Debt -
Total Equity 111.68
Total Capital 111.68
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 2.8835.9856.410.8600.010.020.080.280.98
Operating Cash Flow 15.18-20.79-35.14-48.11-72.59-51.16-180.08-633.81-2,230.80-7,851.69
Capital Expenditure -0.11-0.68-0.16-0.42-0-0-0-0.01-0.04-0.13
Free Cash Flow 15.07-21.47-35.31-48.53-72.59-51.16-180.08-633.82-2,230.84-7,851.83
WACC
PV LFCF -47.17-153.05-496.63-1,611.50-5,229.05
SUM PV LFCF -7,537.40

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 8.47
Free cash flow (t + 1) -8,008.86
Terminal Value -123,784.58
Present Value of Terminal Value -82,436.27

Intrinsic Value

Enterprise Value -89,973.67
Net Debt -71.79
Equity Value -89,901.88
Shares Outstanding 92.29
Equity Value Per Share -974.08